Background: the Modification of Diet in Renal Disease (MDRD) method of renal function estimation has not been extensively assessed in elderly patients. We needed to assess which renal function estimate was most suited for drug dose estimation in our population. Method: we compared MDRD with an optimised version of the Cockcroft-Gault (CG opt ) method in a hospital population, using gentamicin clearance as a baseline. Results: MDRD overestimated gentamicin clearance by 29% (P < 0.001, n = 68), while CG opt underestimated by 10% (P < 0.01). Overestimation by MDRD increased with increasing age. This was 12%, 26% and 69% in age groups <65, 65-80 and >80 years respectively (P < 0.001). CG opt underestimated renal function by −5%, −16% and −4% respectively (P = NS). Bias and precision of renal function estimations for the three age groups were less for CG opt than for MDRD. Age significantly influenced MDRD overestimation in this population (P = 0.037). Conclusion: MDRD overestimated renal function as age increased. While CG opt underestimated renal function, this was of a smaller magnitude, consistent across age, and thus better suited for dose calculation, especially in the elderly. Larger-scale studies using gold standard markers of renal function estimation are urgently needed to determine the accuracy of MDRD in elderly hospitalised patients.
Introduction
The National Kidney Foundation recommends estimation of renal function using equations based on serum creatinine values, suggesting two commonly used approaches. The first is the well-known Cockcroft-Gault (CG) equation, which provides an estimate of creatinine clearance (CrCl) [1] . The second is the Modification of Diet in Renal Disease (MDRD) study, which provides an estimation of glomerular filtration rate (GFR) [2] . This latter equation was developed in a relatively young population (mean age 51 ± 13 years) of chronic kidney disease (CKD) patients, with a view to staging kidney disease, and has subsequently been modified to the 'abbreviated' version commonly used today [3] . Comparative data indicate that the MDRD approach is more accurate than the CG equation in this population [2] . In a young, renally healthy population however (mean age 41 years), MDRD was shown to underestimate GFR by 29% [4] . In a population of older patients with chronic renal insufficiency (age range 69-92), MDRD overestimated renal function by 12%, and did not improve renal function estimation compared to the CG equation [5] .
Historically, published data examining the accuracy of the CG approach have utilised the patient's actual body weight. An optimised version of the CG equation (CG opt ) has been developed that enables a more accurate estimation of renal function [6] . This involves two changes from the traditional CG approach. The first is use of the lesser of actual body weight or ideal weight [50 + 0.9 × (height in cm − 152) for males, 45.5 + 0.9 × (height in cm − 152) for females]. It is known that without adjustment for obesity, CG markedly overestimates renal function [7] . The second alteration is the capping of serum creatinine at a minimum of 60 µmol/l (0.68 mg/dl). The use of values less than this leads to gross renal function overestimates. Low serum creatinine concentrations can be present in elderly patients due to a decreased muscle mass. Both these adaptations are important for elderly inpatient populations in order to obtain the best renal function estimation, which is of critical importance for dosing of key renally cleared drugs. These two alterations result in significantly improved renal function estimates compared with the standard CG formula. The CG opt approach has not previously been directly compared to MDRD.
Gentamicin is a highly water-soluble antibiotic that undergoes complete renal excretion via filtration, and is well suited as a marker of renal function [8] . Renal function as measured by inulin clearance was identical to gentamicin clearance (Cl gent ) determined by two-point data (51.6 ml/min vs. 52.0 ml/min respectively) in hospitalised patients with stable renal function [9] . In a further study CrCl, as determined by 24 h urine collection, was virtually identical to Cl gent (126.1 ml/min and 124.4 ml/min respectively) [10] .
This comparison was prompted by a need to determine which approach to renal function estimation was most suited for renally cleared drug dose calculation for our elderly inpatient population. Our objective was to compare CG opt with the MDRD approach for estimating renal function in a wide range of hospital inpatients, using Cl gent as a marker of renal function, with a view to assessing suitability for drug dosing purposes.
Subjects and methods
Patients receiving once-daily gentamicin therapy as part of routine inpatient treatment had blood samples drawn nominally at 2 and 14 h post-dose after the first or second dose. In order to avoid sampling during the distribution phase, the first sample was taken at least 2 h post-dose [11] .
Doses were at the discretion of the prescribers, and gentamicin was administered intravenously over 5 min. Serum creatinine was measured from either the blood taken for gentamicin sampling, or a sample drawn within 24 h before or after the gentamicin dose.
Inclusion criteria
Patients above 18 years receiving once-daily gentamicin therapy.
Exclusion criteria
Patients with gentamicin concentrations <0.15 mg/l, dialysis, endocarditis, neutropenia, aminoglycoside allergy, pregnancy, critical illness, rapidly fluctuating renal function or cystic fibrosis.
Ethics' committee approval was obtained at each hospital prior to commencement of patient recruitment and patients gave consent for study participation. The study was consistent with the principles of the Declaration of Helsinki. It was conducted across two general metropolitan teaching hospitals catering for medical and surgical patients, one specialising in care for the elderly.
Patients
Eighty-two patients consented to the study, with 68 patients eligible for analysis. Of the 14 ineligible patients four withdrew; gentamicin was ceased in one, blood samples were inadvertently not drawn in two and seven had gentamicin concentrations <0.15 mg/l. See Table 1 for patient characteristics. All patients had stable renal function at the time of study.
Measurements
CG opt was utilised to estimate CrCl [6] . The lesser of ideal or actual bodyweight was used, and serum creatinine was capped at a minimum value of 60 µmol/l (0.68 mg/dl). The abbreviated version of the MDRD formula was used for estimating GFR [3] . For comparative purposes MDRD values were adjusted for body surface area (BSA) using the formula (weight) 0.425 × (height) 0.725 × 0.007184/1.73 as suggested [12] .
Serum creatinine samples were quantified by the Jaffé method without deproteinisation, using a BM/Hitachi 717 (Hitachi Hitechnologies Corporation, Tokyo, Japan) and a solution of sodium hydroxide (800 mmol/l) and picric acid (25 mmol/l). Creatinine values were measured using assays that were aligned with isotope dilution-mass spectrometry in the interests of standardisation.
Serum gentamicin was quantified by Fluorescence Polarisation Immunoassay Analyzer (FPIA) (Abbott Diagnostics, Abbott Park, IL, USA) with an Abbott AxSYM gentamicin reagent pack.
Gentamicin clearance was calculated using standard onecompartment, first-order pharmacokinetics on a Microsoft R Excel spreadsheet [13] . Student's t-test was used for comparison of parametric data and chi-square for nonparametric data, with the use of Fisher's exact test and Yates correction when appropriate. Linear regression was used to explore the relationship between CG opt and Cl gent as well as MDRD and Cl gent . Analysis of variance was used to further investigate the relationship between Cl gent and MDRD. Analysis was performed using Statistica 5.1 (Statsoft Inc., Tulsa, OK, USA).
Results
The patient characteristics are presented in Table 1 .
Differences between MDRD and Cl gent versus age, and between CG opt and Cl gent are presented in Figure 1 , as both the percentage difference (A and B) and the absolute difference in ml/min (C and D). Overall, CG opt underestimated renal function compared to Cl gent by 10%, and this was consistent across nominal age groups of <65, 65-80 and >80 years (see Appendix 1 in the supplementary data available at Age and Ageing online). MDRD overestimated renal function compared to Cl gent by 29%. MDRD increasingly overestimated renal function relative to Cl gent increasing from 12 to 26 to 69% across the <65, 65-80 and >80 years groups respectively (P < 0.001). Capping serum creatinine at a minimum of 60 µmol/l (0.68 mg/dl) for MDRD caused the mean difference between MDRD and Cl gent to decrease to 23% for all patients, but the significant trend for increasing differences between MDRD and Cl gent across increasing age groups remained intact (P = 0.001). Patients were on average 12.7 kg heavier than their ideal bodyweight, subsequently reducing CG opt estimations by 17% compared to CG estimations without this adjustment. Fifteen patients had serum creatinine <60 µmol/l (0.68 mg/dl). Not capping the serum creatinine for CG opt marginally increased the renal function estimation by 2.3 ml/min, which was 6.4% less than the mean Cl gent .
For CG opt and MDRD, 94% and 79% of estimations were within 50% of Cl gent respectively (P = 0.001). For patients less than 65 years of age, 2 of 26 patients (8%) had MDRD estimations that were >50% of the Cl gent value, compared to 12 of 42 patients (29%) greater than 65 years of age (P = 0.056). For CG opt , all estimations for patients less than 65 years of age were within 50% of Cl gent , with four estimations (6%) >50% outside the equivalent Cl gent in patients greater than 65 years of age (two above and two below).
Linear regression analysis comparing CG opt renal function with Cl gent displayed a good correlation (r 2 = 0.55, P < 0.001). MDRD renal function versus Cl gent resulted in a weaker correlation (r 2 = 0.35, P < 0.001). This improved when serum creatinine was capped at a minimum of 60 µmol/ l (0.68 mg/dl) (similar to CG opt ) for calculations (r 2 = 0.48, P < 0.001).
Characteristics of patients with MDRD that overestimated by 50% or more relative to Cl gent were compared to those where MDRD was within 50% of Cl gent . Analysis of variance was performed using age, weight, height and serum creatinine as variables ( Table 2 ). The presence of lower serum creatinine and lower weight significantly influenced the overestimation of MDRD, while increasing age just failed to reach significance (P = 0.059). Half of the patients with overestimated MDRD values had a serum creatinine <60 µmol/l (0.68 mg/dl), which was the minimum input for serum creatinine values utilised in CG opt . An identical comparison was performed using MDRD estimations with a minimum serum creatinine value capped at 60 µmol/l (0.68 mg/dl), in order to bring it into parity with CG opt . With this adjustment, increasing age was the only variable with a significant impact on MDRD overestimation (P = 0.037). Current recommendations suggest further investigation for CKD for any patient with an MDRD renal function of <60 ml/min/1.73 m 2 . MDRD predicted that 78% of this group had renal function >60 ml/min/1.73 m 2 . This was significantly higher than both CG opt and Cl gent which predicted 44% and 57% of patients respectively (P < 0.001 and P = 0.010 respectively for comparison with MDRD). There was no difference between CG opt and Cl gent (P = 0.12).
Discussion
The MDRD approach overestimated renal function in selected elderly patients when using Cl gent as a baseline renal function indicator. This overestimation was age dependent and did not become apparent until after 65 years of age, a population that has rarely been studied for MDRD renal function estimation. Other groups have already noted the increasing disparity between MDRD and non-optimised CG estimates with increasing age, but due to the lack of an objective marker of renal function were unable to ascertain the extent to which either approach may have been at fault [14] [15] [16] . These investigators did, however, find differences of a similar incidence and magnitude in renal function estimations when comparing MDRD with CG in elderly populations [14, 15] . While increasing age appeared to drive this overestimation, the effect was variable and was not solely reliant on increasing age. A serum creatinine in the low-normal range as well as decreasing height and decreasing weight may also drive this effect [15, 16] . When all of these variables are simultaneously at extremes to those seen in the population that the MDRD equation was based on, the difference between MDRD compared to CG opt is greatest [16] . In this manner there may be a marked variation in the degree of overestimation by MDRD in elderly patients, ranging from negligible to clinically significant, and this may explain why the overestimation of MDRD in the elderly has gone largely un-noticed until now. In this study patients that were overestimated by 50% or more using MDRD were significantly lighter and with lower serum creatinine than those who were not, while increasing age just failed to be a significant influence. When MDRD was calculated using a minimum serum creatinine of 60 µmol/l (0.68 mg/dl), in order to bring it into parity with the way serum creatinine was utilised within the CG opt equation, only age was a significant variable for MDRD overestimation relative to Cl gent .
Patients with >50% discrepancies between MDRD and Cl gent in this study were on average 23 years older, 16 kg lighter, 5 cm shorter and with serum creatinine 113 µmol/l (1.28 mg/dl) lower than the population used by Levey et al. to develop the MDRD equation [2] . It may be unreasonable to expect MDRD to accurately predict renal function in this group of patients, who possess markedly different characteristics to the population it was developed in. On the background of an ageing population in the developed healthcare systems, it is essential the elderly are defined and studied as a group within their own right [17] .
The CG opt equation, while underestimating renal function compared to Cl gent , was not influenced by age. It was better suited as a marker to guide dose adjustment of renally cleared drugs in this population. The non-optimised CG equation estimates ClCr, which is an overestimate of GFR, especially at low GFR values, due to the tubular secretion of creatinine. This was also the case in this study, but once the CG formula was corrected for bodyweight and the serum creatinine capped, the optimised version produced a renal function estimate lower than CL gent .
This analysis showed that MDRD grossly overestimated renal function in a number of elderly patients, but not so for CG opt . While the mean absolute differences between MDRD and renal function were not huge (15 ml/min), the major differences were seen in the elderly, and these were often in the order of 30-50 ml/min. Overestimation of renal function by this amount has potentially huge ramifications for dosing in a patient whose baseline renal function is <50 ml/min. Renal function overestimation will result in relative overdosing of renally cleared drugs. The elderly are more likely to experience adverse drug events and be hospitalised longer for it [18] . Corsenello et al. demonstrated a doubling in the rate of adverse drug events for renally cleared drugs for patients with impaired renal function compared to those with normal renal function, driven by a lack of dose adjustment [19] . This makes MDRD unacceptable for calculating doses of renally cleared drugs in an elderly population. It has been shown that there would be huge increases in dosing for elderly patients compared to those in conventional practice should MDRD values be used as the basis for dosing [16] . While CG opt underestimated renal function in this group by 10%, this was more accurate than MDRD, and consistent across all ages, hence better suited and safer for drug dosing purposes in this population.
There is an urgent need for further investigation of MDRD as an estimate of renal function in older hospitalised patients. The general acceptance of MDRD has been rapidly accelerated due to its automatic generation on all laboratory reports containing a serum creatinine value. This has occurred especially in the hospital setting where serum creatinine is often ordered on a daily basis. Current recommendations indicate that MDRD should not be used for drug dose calculation, and this is supported by our study. Use of MDRD in the hospitalised elderly would lead to inadvertent overdosing if used for such a purpose.
Very low serum creatinines (<60 µmol/l (0.68 mg/dl)) are occasionally seen in the elderly. Use of these very low serum creatinine values to estimate renal function invariably results in gross overestimates. For this reason a minimum cap on serum creatinine has been suggested [4, 6, 20] . This approach has led to better estimates of renal function and should be investigated as a possible means of improving the accuracy of MDRD. Capping the serum creatinine in this group for MDRD improved its ability to estimate renal function when using Cl gent as a marker. It did not however significantly alter the overestimation in renal function by MDRD in the elderly patients.
This study is limited by relatively small numbers and the use of Cl gent as a comparator. Gentamicin is an accurate indication of renal function, but is not considered a gold standard [9, 10] . The study needs to be reproduced in a larger population using gold-standard renal function measures. Only the abbreviated form of the MDRD equation was used in this comparison.
The CG opt method of renal function estimation is the preferred approach for determining doses of renally cleared drugs in a hospitalised population containing elderly patients. The abbreviated version of the MDRD equation overestimates renal function in a clinically significant proportion of elderly patients, making its use potentially dangerous for this purpose. This may also hinder the screening accuracy of MDRD in this population.
Key points
r MDRD grossly overestimates renal function in selected elderly patients. r MDRD renal function estimations should not be used to calculate drug doses in the elderly. r A modified version of Cockcroft-Gault was best suited for drug dose calculations in the elderly.
